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ABSTRACT 
Evaluation of published methods reveals that existing methods for saliva sampling do not 
address the physical chemical attributes of volatile organic compounds (VOC). This study 
describes and presents evidence for adopting  in-situ sampling of salivary VOC directly from 
the oral cavity using a polydimethylsiloxane (PDMS) based sampler. In-vitro studies indicated 
that the vapour pressure of analytes was a factor in both the recovery of analytes, and in the 
precision of the recovery. The highest recoveries were observed for VOC with the lowest 
vapour pressures, for example 5-nonanol (vapour pressure (Pv) = 14 PA) recoveries were 
approximately 20-times greater than those observed for octane (Pv = 1726 PA). Similarly, 
relative standard deviations reduced with vapour pressure, with the RSD for 5-nonanol 
responses observed to be  2.7 % to compared to RSD = 26 % for octane. Evaluation of VOC 
recovered from 6 in-vivo samples indicated that VOC concentrations in saliva may follow log-
normal distributions; log-normal RSDs falling between 4.4% to 18.2% across the range of 
volatilities encountered. Increasing sampling time from 1 to 30 minutes indicated that the 
recovery of VOC into the sampler was effected by interaction between different physical 
chemical properties and biogenic flux. A sampling time of 10 min was found to offer an 
acceptable compromise that enabled a representative sample to be acquired for the widest 
range of observed VOC behaviours with the sampler. The potential to ‘tune’ the sampling 
protocol for targeted analysis based on these factors was also noted.  
Comparison with passive drool saliva collection revealed up to 105 enhancment with 
reduced variability compared to drooled samples. This approach to in-situ saliva sampling 
appears to have significant analytical utility for studying volatile signatures in humans.  
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INTRODUCTION 
Human saliva is a highly variable and individualised biological fluid blended from: the 
secretions of the salivary glands; gingival crevicular fluid; bacteria and their metabolites; 
epithelial cells; and food debris, in various stages of decomposition [1]. The composition of 
whole saliva varies with circadian rhythm as well as in response to physiological and 
pathological factors such as taste and smell stimuli as well as metabolic influences 
associated with age; menstrual cycle; physical exercise; and psycho-emotional state. The 
use of prescription pharmaceuticals and or narcotic substances also effects saliva [2]. 
Exogenous VOC insults will also show-up in the chemical profile of saliva [3 and 4]. Finally 
the state of hydration of the individual needs to be included in this list. 
The presence of a compound in saliva is determined by its chemical functionality and 
structural characteristics. Lipophillic and neutral molecules pass from blood to saliva more 
efficiently than hydrophilic and ionised molecules [5]. The high water level and low protein 
content of saliva means that strongly protein-bound compounds are unlikely to be present in 
this matrix [6 and 7].  
Saliva sampling and analysis have been used to: monitor toluene exposure and other 
hazardous VOC in a polymer processing workforce [3 and 4]; measure 3-methoxy-4-hydroxy-
phenylglycol as a marker of anxiety [8]; diagnose gout from elevated levels of uric acid [9 ]; 
provide a rapid primary diagnosis of renal disease through uric acid and p-aminohippuric 
acid determination [10], characterise pharmokinetic profiles of dehydroepiandrosterone and 
cortisol following corticosteroid administration [11]; indicate cannabis use by measuring Δ
9-tetrahydrocannabinol [12] and cocaine administration through determination of cocaine, 
anhydroecgonine methylester, ecgonine methylester  and cocaethylene [13]; and to study 
dietary factors such as fatty acid [14], and caffeine [15 and 16]. Saliva characterisation has 
also been proposed in relation to systemic diseases such as cystic fibrosis, multiple 
sclerosis, diabetes mellitus, alcoholic liver sclerosis, acquired human immunodeficiency 
syndrome and kidney dysfunction [17], as well as its application for qualitative toxicological 
screening [5].  
Quantitative analysis of saliva specimens has indicated meaningful correlations between un-
bound plasmatic and salivary levels of analytes [7, 8 and 17]. (Note that VOC present in 
3 
 
plasma as bound complexes are less correlated to salivary levels.)  The non-invasive nature 
and ready accessibility of the sample suggests that saliva may be an attractive alternative to 
blood and urine for profiling and screening, human and animal subjects, for biological 
markers. 
Protocols for collecting saliva samples include bespoke methods that collect the specific 
excretions from individual salivary glands; enabling comparison between gland secretions. 
However, such approaches require high-levels of specialist training to enable reliable 
sampling. The most common approach, for it is a practical and straightforward procedure, is 
to collect whole saliva. Even so, this approach requires carefully framed and rigorously 
conducted protocols to ensure consistency between samples and subjects. Whole saliva can 
be induced using mastication or citric acid, known as a stimulated method. Alternatively  
participants may be asked to spit into a vial or to sit quietly while their saliva drains off their 
lower lip into a collection vessel, known as passive drool, may be employed and such 
approaches are termed unstimulated methods[ 18]. Introduction of citric acid to stimulate 
saliva lowers the pH which alters the transport properties of some analytes, testosterone for 
example, and so the most commonly used method for collection of stimulated saliva uses 
the Salivette [18]. The Salivette is a cotton roll that the participant chews until it is 
saturated, after which the sample is recovered by centrifugation. The use of cotton wool 
introduces artefacts into the analysis and has been reported to enhance or reduce the 
results of immunoassays [18]. A study comparing bacterial levels in unstimulated samples 
obtained from spitting and passive drool reported 14-fold more bacteria in specimens 
obtained from spitting than those obtained by passive drool [18]. Bacterial action within a 
saliva sample is a vital factor operating from the moment sampling starts hence the passive 
drool approach is commonly adopted to minimise such effects [19].  
A Standardised saliva collection method has yet to be realised ,and poor compliance with 
the many varied interpretations of sampling protocols have been reported [20]. It appears to 
be accepted that obtaining representative and reproducible whole saliva samples is a non-
trivial task. Once collected sample handling and storage procedures are also important with 
bacteria in the sample continuing to metabolise compounds and degrade the samples’ 
integrity. Many salivary constituents have a short biological half-life, and rapidly degrade 
after sample collection. Further, the more volatile components are likely to be lost to the 
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headspace or adsorbed/absorbed onto the surfaces of the materials used during collection 
and storage (cotton wool for instance). Storage procedures specify freezing, or cooling, 
saliva samples to stabilise them and inhibit bacterial degradation action, often neglect 
volatility. One review of the salivary specimen as a new tool for investigation recommends 
aliquoting immediately on collection followed by storage at 4ºC, -20ºC or -80ºC depending on 
the proposed storage time [18]. Volatility was not a factor in such discussions. Other sample 
stabilisation steps include inhibition of enzyme or bacterial activity by snap freezing, or 
addition of inhibitors, denaturing agents or sodium azide for example [2 and 18]. Such 
measures are time consuming, increase the number of steps in the analytical pathway, and 
are susceptible to human error, while ensuring  significant ventilation of the sample’s 
headspace with the attendant loss of volatiles. The resultant sampled material may well not 
be truly representative of the salivary composition at the moment of sampling [18]. The 
challenges associated with reproducible collection and storage of saliva samples as well as 
the plethora of pre-treatment techniques necessary for a range of analysis techniques have 
been reviewed elsewhere [1, 2, 16, 17, 18, 21, 22 and 23].  
Many of these challenges have been addressed by adopting solid phase microextraction 
(SPME), for SPME offers simplicity, speed, reliability, and flexibility. Time-consuming pre-
concentration is reproducibly achieved during sampling, and SPME integrates easily with GC 
instrumentation. Although SPME offers many improvements over established saliva 
sampling techniques for volatile components the challenges associated with standardisation 
of collection, stabilisation and storage of drooled saliva still exist. 
This study adopts a polydimethylsiloxane (PDMS) based sampling approach, previously 
described for sampling VOC from human skin [24] to in-vivo sampling of saliva within the 
mouth for VOC. This approach removed the pre-treatment, collection and handling 
complications associated with drooled/expressed saliva methods. This new approach was 
straightforward to use and compliance with the sample protocol was achieved more reliably. 
With sampling times between 1 and 30 minutes, “rich” and complex gas chromatography-
mass spectrometry (GC-MS) VOC profiles may be obtained with up to 600 resolved and 
partially resolved components.  
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EXPERIMENTAL 
Ethics and participant preparation 
The study was conducted in accordance with the ethical principles of Good Clinical Practice 
and the Declaration of Helsinki. The local ethics committee (Ethical Advisory Committee, 
Loughborough University, Loughborough, LE11 2DT) approved the studies references G10-
P23 and G10-P24, and all participants were healthy adult volunteers who gave written 
informed consent. 
Participants were aged 18-35 and were recruited from Loughborough University staff, 
students and their social networks. A brief introduction and familiarisation with the 
procedure was given to participants before the beginning of the study and before each 
sample was taken. Participants were asked not to eat, nor drink anything, other than 
unflavoured water, brush their teeth or use any personal care products on the morning of 
their study visit. All samples were taken in a small internal room at the Centre for Analytical 
Science within the Chemistry Department at Loughborough University. A chaperone, of the 
same gender as the participant, was present during sample collection and access was 
restricted to only those researchers and participants involved in the sampling process. 
Sampling 
In-vivo sampling.  
A saliva sampler, Figure 1 and Table 1,  was designed and built that consisted of a solid 
phase extraction cartridge (Cat no: C-SPTD5-6MM Markes International Ltd) mounted on a 
threaded pin that screwed securely into a stainless steel holder that could be placed 
underneath the tongue in an analogous manner to an oral thermometer. The solid phase 
extraction cartridge cartridges were made from a titanium cylinder coated externally with 
polydimethylsilicone.  Prior to use the cartridges were placed in a thermal desorption tube 
(Cat no: C0-BXXX-0000 Markes International Ltd) and conditioned with 50 cm3 min-1 of 
helium at 190ºC for 60 min. Once conditioned the Samplers were analysed by thermal 
desorption gas chromatography mass spectrometry (TD-GC/MS) to ensure that  they were 
free from unacceptable levels of VOC contamination as well as providing a final  “polish” 
prior to use with the study’s participants. 
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<Table 1 Near here. > 
<Figure 1 near here> 
Immediately prior to sampling the saliva sampler was assembled, with care taken not to 
handle the solid-phase extraction cartridges by using stainless steel tweezers. The sample 
procedure commenced with the participant drinking 50 cm3 of unflavoured water to refresh 
their mouth. 1 min later the participant placed the saliva sampler into the sublingual region 
of the mouth. They could use the handle to stabilise and reposition the saliva sampler if 
needed, see Figure 1. At the end of sampling the participant removed the saliva sampler by 
drawing it through their closed lips to remove any excess liquid from the surface. The 
investigator immediately unscrewed the spindle and placed the solid-phase extraction 
cartridge into a clean glass thermal desorption tube that was then sealed and stored in an 
airtight container at 4ºC until analysis. Samples were not stored any longer than 24 hr 
before analysis. The samples were removed from storage immediately prior to analysis. 
Passive Drool. 
Whole saliva samples for comparative studies using a passive drool approach were 
collected. The participant was seated with their head tilted forward to cause saliva to pool in 
the front of their mouth. The saliva was allowed to flow from their mouth into a glass 
collection vessel fitted with a screw top cap. This process was repeated until approximately 
3 cm3 of saliva had been collected. 1.8 cm3 was immediately transferred to a 2 cm3 vial and 
a solid-phase extraction cartridge fitted to the stainless steel spindle was added rapidly 
before the vial was sealed. It was important that these procedures were undertaken as 
quickly as possible to minimise headspace losses. At the end of the extraction time the 
solid-phase extraction cartridge was removed and quickly and gently wiped with a lint-free 
wipe ( ‘Kimcare’ Kimberly-Clark Professional) to remove excess fluids and then placed 
immediately into a thermal desorption tubes for that was promptly sealed and stored at 4ºC 
before analysis within 24 hr.  
Instrumentation 
VOC were recovered from the sampler with a two-stage thermal desorption procedure 
(Markes International Ltd Unity2 Thermal Desorber), isolated with a 60m long capillary 
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column with a 5% phenyl, 95% methyl polysiloxane stationary phase (Cat no: 122-5562 
Agilent DB-5MS) and detected using a quadrupole mass spectrometer (Fisons Trio 1000). 
Table 2 summarises the instrumental parameters.  
<Table 2 near here> 
SAMPLER CHARACTERISATION STUDIES  
Three studies were undertaken to evaluate this approach to characterising the VOC present 
in human saliva: reproducibility, the effect of sampling time and an evaluation against 
passive drool-based approaches. 
Reproducibility 
The reproducibility of the technique was assessed both in-vitro and in-vivo. 
In-vitro  
An aqueous 1 ppm (v/v) standard of five probe compounds, octane, heptanal, methyl 
hexanoate, nonanol and 2-decanone, representing classes of compound previously 
observed in human saliva [ 25 ] and spanning a representative range of chemical 
functionality was prepared. 1.8 cm3 of this standard was placed into a 2 cm3 headspace GC 
sample vial to minimise the headspace whilst allowing for liquid displacement during 
sampling with a solid-phase extraction cartridge mounted on the stainless steel spindle. The 
vial was sealed and left to stand in a thermostatically controlled oven at 37ºC for a sample 
time of 5 min. At the end of the 5 min sample time the solid-phase extraction cartridge was 
removed and quickly and gently wiped with a lint-free wipe to remove excess water and then 
placed immediately into a thermal desorption tubes for analysis. This procedure was 
repeated a further five times with a fresh aliquot of standard for each replicate. 
In-vivo 
Six samples were taken from the sub-lingual region of the mouth of a female participant 
using the procedure described above with a sampling-time of 5 min.  The participant was 
allowed to rest for 1 min between each sample.  
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In-vivo sampling time 
Six samples taken with sample times 1min, 3min, 5min, 10min, 20min and 30min were 
taken from the sub-lingual region of the mouth of a female participant following the 
procedures described above. The order of sampling was randomised.  
Comparative evaluation, in-situ vs. extraction from “passive-drool” samples. 
A 10 participant, (5 male and 5 female) double cross-over design was adopted. Each 
participant provided samples during two separate study visits when they gave in-situ and 
passive drool samples, see Table 3. Samples were taken before 09:00 hr. on the day of the 
study visit following the protocols described above. Saliva samples obtained by in-situ 
sampling and passive drool were extracted for 10 min. 
RESULTS AND DISCUSSION 
None of the participants reported any problems arising from using the saliva sampler. No 
irritation or discomfort was noted and the procedure was well-tolerated.  
Reproducibility 
The results from the in-vitro reproducibility study are summarised in Table 4 and Figure 2. 
The underlying processes controlling the recovery of the probe molecules into the PDMS 
phase include adsorption followed by diffusion and permeation and these will be a function 
of concentration, volatility, hydrophobicity and functionality/polarity. The most important 
predictive molecular characteristic appears to be vapour pressure at 25 °C.  As the vapour 
pressure increases so does the RSD. The amount of material recovered is also inversely 
correlated to the vapour pressure with the size of the chromatographic response increasing 
logarithmically with reciprocal vapour pressure, see Figure 3. Such trends indicate that the 
most volatile compounds are highly susceptible to small variations in sampling procedures, 
most rapidly lost from the experiment and recovered with the lowest efficiency; a similar 
observation has been noted previously [22].  
<Table 3 and Figures 2 and 3 near here> 
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Figure 4 illustrates the complexity of the chromatography obtained from in-vivo samples with 
approximately 100 resolved and many more unresolved chromatographic peaks evident. 
Peak intensities ranging between two to three orders of magnitude.  
Eight randomised peaks selected from the study were assessed for normal and lognormal 
distributions using the Anderson-Darling test [26],and the cumulative distribution function 
appeared to fit a lognormal distribution more closely than a normal one. Indeed log-normal 
distributions are often observed in biological systems; cell division of bacteria, latent periods 
of infectious diseases, permeability and solute mobility in plant cuticles for example  as well 
as antibody concentration in human blood sera [27 and 28]. The “S”-shaped curves, linear 
probability plots, and symmetric distribution expected in normally distributed data were not 
observed, Figure 5 provides an example of this behaviour.  
For the in-vivo reproducibility data six compounds were selected at random across the 
chromatogram and where appropriate identified from NIST mass-spectral matches: 
propanoic acid, an unassigned entity, 2-phenoxy ethanol, n-hexyl salicylate, benzoic acid 
ester-1, and finally another benzoic acid ester.  For these probe compounds the hypothesis 
of normality was rejected and a log-normal distribution was adopted on the basis that, no 
significant departure from a log-normal distribution was observed for any them. Figure 5 
illustrates this behaviour for the unassigned alkybenzoate (benzoic acid ester-1). Such 
observations lead to the inference that the levels of VOC in human saliva may follow a log-
normal distribution, see Table 5 and Figures 4 and 5.  
The data from the in-vitro and in-vivo studies were consistent with a methodology that 
performed in a predictable and reliable way. Importantly these observations highlighted the 
priority of sample management in the analytical work-flow, especially for the most volatile 
components within saliva samples, with recovery and reproducibility strongly influenced by 
the volatility (expressed as vapour pressure) of the prospective analyte. 
In-vivo sampling time 
Figure 6 is a histogram that presents the chromatographic peaks for ethanoic acid, 6-
methyl-5-hepten-2-one, heptadecane and, an unidentified alkylbenzoate against sampling 
time. The nature of the chromatography for different elements of the chromatogram is 
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discernable along with the degree of enhancement that is possible by increasing sampling 
time. It is evident that increasing sampling time beyond a limit does not result in increased 
recoveries of the VOC, and the competitive equilibration processes may be discerned.  
Ethanoic acid, was accumulated rapidly over the first 5 min of sampling. After this the rate 
slowed reaching a maximum between 5 and 10 min. A further increase in sampling time 
resulted in a reduced response. Methyl-5-hepten-2-one showed a similar trend of an 
accumulation to a maximum value followed by a reduction in recovery; in this case the 
maximum recovery was achieved with a sampling time of ca. 15 min. The less volatile 
heptadecane and the unidentified alkylbenzoate,  present at significantly lower levels, were 
accumulated with a gradual increase in abundance over 10 min before tending to 
equilibrate with the sampler.  
The underlying physical chemistry and metabolic/catabolic processes governing these 
behaviours are likely to involve a combination of: partitioning of VOC from the saliva into the 
PDMS phase of the sampler cartridge, the continual release of metabolites/catabolites into 
the saliva and the kinetics of permeation and diffusion of the compounds into and out of the 
PDMS phase. The role and effect of the different factors on the mass-transport function for 
each of the many compounds in the VOC saliva profile will be different and reflect the 
functionality of the compound, its volatility and saliva concentration. Initially, VOC in the 
saliva may be viewed as partitioning into the PDMS driven by concentration gradients, and 
more volatile species are likely to penetrate further and accumulate more rapidly in the 
sampling medium (PDMS). The kinetics of less volatile, and perhaps lower concentration, 
components will be reflected in a slower accumulation. However, the partition coefficients 
for compounds of this nature are higher and so as sampling progresses the PDMS sampling 
phase moves closer to equilibrium with the surrounding saliva and competitive 
adsorption/absorption processes would result in the displacement of the more volatile 
components; Equation 1 is helpful in visualising such phenomena. 
ሾ݅ሿPDMS ൌ ܭ௜	ሾ݅ሿsaliva1 ൅ ܭ௜	ሾ݅ሿsaliva ൅ ∑ܭ௝	ሾ݆ሿsaliva 
Equation 1
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The equilibrium concentration of an analyte in the PDMS sampling phase (ሾ݅ሿPDMS) may be 
expressed in terms of the partition constant of the analyte between saliva and PDMS (ܭ௜), 
the concentration of the analyte in saliva (ሾ݅ሿsaliva), and the sum of the products of the 
concentrations and equilibria constants of the competing co-absorbed species (∑ܭ௝	ሾ݆ሿsaliva). 
A second partitioning process also needs to be considered and that is volatilisation into the 
gas phase from the PDMS phase. This will start as soon as the sampler is removed from the 
saliva. Fast transfer to the thermal desorption tube is important to minimise evaporative 
losses and a similar rapid transfer during the thermal desorption procedure is important too. 
The trends in Figure 3 and Figure 6 reflect these processes, and the sensitivity of volatile 
components to small changes in sampling processes as already been noted above. 
The approximate trends between sampling time and recovery (solid lines in Figure 6) 
illustrate the point that the optimal conditions for sampling will be different for each analyte 
and the challenge for profiling VOC in saliva is to develop a method that provides an 
accurate representation of as many compounds within the target range of the profile as 
possible. Conversely, this also highlights the inherent selectivity of such techniques and the 
opportunity to ‘tune’ sampling methodologies for targeted analysis.  
Figure 6 indicates that 10 min appears to be an acceptable operational compromise for a 
sampling time and this was the sampling time used for the rest of this study.  
Comparison with passive drool 
Figure 7 shows that the chromatography obtained from the two sampling techniques was 
fundamentally different. While there are many qualitative similarities, with around 70% of 
components present in both cases, the differences in intensity were marked. This was 
especially the case at higher retention times. 
The higher recoveries from the in-situ sampler may be the result of contact between the 
sampler and the surface membranes of the mouth, or the degradation of these compounds 
once expressed from the mouth. Headspace losses and bacterial degradation may 
reasonably be anticipated with passively drooled samples. The comparative study was 
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definitive in establishing that VOC recoveries were for the most part greater from in-situ 
sampling. 
CONCLUSION 
The reduction of puncture wounds for blood sampling is an end goal of this research, for the 
increasing prevalence of antibiotic resistant infectious pathogens encourages the 
development of new diagnostic approaches that are intrinsically non-invasive. The sampling 
technique described in this study was well-tolerated by our volunteers. Nevertheless a 
sample time of 10 min is likely too long to be practical for many envisaged situations. It may 
be possible to reduce the sampling time to 1 min with changes in the sampling cartridge 
construction and the materials used to make it from. What is clear is that this is a simple, 
reproducible fast and easy to administer approach that may have applications in many 
diagnostic and metabonomic /metabolomic studies.  
Another important element of this research was to develop an analytical work-flow for saliva 
that was compatible with other in-vivo VOC sampling and analysis methods; breath and skin 
for instance [22,  29]. Long-term storage stability of samples has not been addressed in this 
work and will be the subject of future studies. Approaches are likely to include quench 
freezing in liquid nitrogen or fast re-trapping onto sorbent beds. 
In adopting this methodology care needs to be taken to ensure sampling times are carefully 
controlled and if possible matched to the volatility of the analytes under study. Enhanced 
sensitivity and selectivity may be achieved by careful optimisation. Conversely, it is possible 
to introduce bias if this factor is not carefully managed.  
The tentative observation of log-normal distributions is potentially important and may have 
wider ramifications with other in-vivo VOC measurement techniques. A follow up study with 
this as the main focus would be a logical next step int his regard. 
Comparison of in-situ sampling with passive drool collection has revealed that in-situ 
sampling provides more analytical information with lower intrinsic variability compared to a 
passive drool approach. The responses in this study are encouraging and indicate significant 
analytical utility for this form of in-situ sampling. There is sufficient sensitivity and precision 
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to enable these data to be included with existing breath and skin analysis methods in VOC 
profiling and biomarker prospecting studies.  
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Figure 1. Saliva sampler.  Clockwise from top left. A titanium cylinder coated with 
polydimethylsiloxane is held in place by two springs inside a glass thermal 
desorption tube. Once conditioned the cylinder was removed and placed onto the 
threaded stainless steel spindle that was then screwed into the holder, (Right). 
The assembled sampler could then be placed comfortably into the mouth of a 
participant where a VOC sample was collected in-vivo (Bottom left). 
 
Figure 2.  The six replicates from the in-vitro reproducibility study. Six replicate samples of a 
1.8ml aliquot of an aqueous standard containing 1ppm octane (1), heptanal (2), 
methyl-heanoate (3), 5-nonanol (4) and 2-decanone (5). Also labelled are 
compounds from the PDMS sampling medium (A-D). 
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Figure 3.  Examination of the recovery data (circles) and reproducibility data (diamonds)in 
Table 4 from the in-vitro reproducibility reveals how vapour pressure predicts the 
recovery and reproducibility of VOC.  These two plots show how RSD increases,  
and recovery reduces, with vapour pressure. These data are plotted relative to 
those of octane to   enable both trends to be viewed easily on the same graph.  
 Data for octane (Tabl e 4), Pv: 1726 Pa at 25°C, A: 20 kcount s, and RSD: 26%. 
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Figure 4. Top: An example chromatogram of a VOC in saliva profile obtained from in-vivo 
sampling with a polydimethylsilicone cartridge sampler, (Tables 1 and 2). Bottom: 
The corresponding response from a sampler blank. Traces are magnified x 5 with 
a 3 MCounts cut of for the blank and a 10 MCounts cut-off for the saliva trace. 
 
Figure 5. Example of evidence for log-normal distributions of VOC  concentrations in human 
saliva. Cumulative frequency curves for Component 5 in Table 5 a benzoic acid 
ester tr =2616 s. Showing normal (A) and log-normal (B) distributions, histograms 
for normal (C) and lognormal (D) distributions and probability plots for normal (E) 
and lognormal (F) distributions suggest a lognormal distribution of VOC levels in 
the participant studied for in-vivo reproducibility.. 
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Figure 6.  A histogram showing the  effect of sampling time on the recovery of: ethanoic acid 
(A, tr 5.9 min ); 6-methyl-5-hepten-2-one (B, tr 25.1 min);  heptadecane at x10 
magnification (C, 73.8 min); and, an unidentified alkylbenzoate at x 100 
magnification (D, 112.6 min). The deconvolved peaks for these VOC are shown 
against different sampling times. The solid lines provide an indication of the 
general trends of accumulation, and show the combined effects of the partition 
constants, concentration gradients, and the metabolic/catabolic release into the 
oral cavity. 
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Figure 7.  A comparison of the GC profiles observed from a PDMS in-situ sample bottom, 
and from a passive drool, offset at 30 Mcount. The top trace shows the log of the 
relative responses (Log10(Iin-situ/IDrool)  for all the peaks with an intensity of greater 
than 1 % of maximum. The differences in the profiles indicated significant 
enhancement in signals obtained from the in-situ samples. 
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Table 1. Summary of design parameters for the saliva sampler. 
Parameter Dimension 
Cartridge  
Hollow titanium rod coated inside and out with PDMS (Markes International, Part Number C-SPTD5-6MM) 
Sorbent Polydimethylsiloxane (PDMS)   
Configuration   
Length 6  mm 
Outer Diameter 2. mm 
Inner Coating Thickness 1 µm 
Outer Coating Thickness 500 µm 
Holder   
Material Stainless Steel (grade SST-316) 
Total Length 101.19  mm 
Handle Diameter 5.93  mm 
Cartridge Mount Diameter 1.25  mm 
Cartridge Mount Head Diameter 3.96  mm 
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Table 2.  Summary of instrumentation operating parameters. 
Parameter Setting  
Markes  International  Unity 2 Thermal  Desorption  Conditions 
Primary desorption flow  50  cm3min-1 
Primary desorption temperature 180  oc 
Primary desorption split Splitless  
Primary desorption time 5.0 min 
Cold trap. Markes International UK general purpose hydrophobic cold trap (Part No U-T2GPH-2S)   
Cold trap low temperature -10 oC 
Secondary desorption flow  1  cm3 min-1 
Secondary desorption temperature 300 oC 
Secondary desorption split Splitless  
Secondary desorption time 5.0  min 
HP  5890  Gas Chromatograph Conditions
Column DB5 MS   
Column length 60 m 
Column diameter 0.25 mm 
Stationary phase film thickness 0.25 μm 
Column flow: constant pressure 25 psi 
Carrier gas Helium  
Temperature program A B  
Start temperature (hold time) 40(0.0) 30(0.0) oC (min) 
Temperature ramp rate 5 2 min 
End temperature (hold time) 300 (8.0) 300 (8.0) oC (min) 
Total run time 60 140 min 
Fisons  Trio. 1000  Mass  Spectrometer  Conditions 
Scan type TIC  
Mass  range 40 to 445   m/z 
Scan time 0.45  S 
Interscan delay 0.05 S 
Ionisation EI+  
Total run time 60  140 min 
Source Temperature 200ºC ºC 
Interface Temperature 250ºC ºC 
Note. A: Temperature program for reproducibility studies 
 B:Temperature program for sampling time and comparison-evaluation studies 
4 
 
 
Table 3. Summary of the sampling campaign adopted for the in-situ vs. passive drool evaluation study. 
Sample order F-02 M-03 M-04 M-05 M-06 F-01 F-07 F-08 M-10 F-09 
1-1 I-S#01 I-S#03 P-D#01 I-S#09 I-S#13 P-D#15 P-D#17 P-D#19 P-D#23 I-S#25 
1-2 P-D#02 P-D#04 I-S#08 P-D#10 P-D#14 I-S#16 I-S#18 I-S#20 I-S#24 P-D#26 
2-1 P-D#05 P-D#11 I-S#33 P-D#21 P-D#39 1-S#37 I-S#31 I-S#27 I-S#35 P-D#29 
2-2 I-S#06 I-S#12 P-D#34 I-S#22 I-S#40 P-D#38 P-D#32 P-D#28 P-D#36 I-S#30 
 
Note:  Sample order: x-y where x: visit number and y: sample number. The participant code designates gender (M/F) and their 
study identifier number.  Each sample is designated as I-S: in-situ or P-D passive drool followed by the position in campaign 
sequence #. The order of the participants reading left to right designates the order of their recruitment to this study.  
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Table 4. Summary of the in-vitro reproducibility study. 
 Compound  M.Wt. Pv/Pa TB/ K Q (m/z) tr/s A/ kcount s RSD 
1 Octane  114.14 1726 399 43 438 20 26 
2  Heptanal 114.10 378 426 70 606 108 23 
3  Methyl hexanoate 130.10 50 423 74 648 272 1.3 
4  5-Nonanol  144.15 14 468 69 966 397 2.7 
5  2-Decanone 156.15 33 484 58 1164 260 5.5 
Note.   M.Wt, relative molecular mass; Pv, Vapour pressure /Pa  at 25 °C (taken 
from Chemspider, www.chemspider.com); TB, Boiling point / K; Q, 
 Quantitation ion  (m/z); tr ,retention time / s; A, chromatographic peak 
area /kcount s; and, RSD, relative standard deviation (%). 
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Table 5 Comparison of Anderson-Darling statistics for 8 peaks selected at random, 
from the  in-vivo reproducibility study. The Anderson-Darling test [ref] is a 
goodness of fit test based on the culmulative frequency function. The AD 
statistic measures how well the data follow a particular distribution, the 
better the fit the smaller AD value. The p-value is the probability of 
obtaining these test results when the assumed distribution of the data is 
true. Therefore when comparing distributions to determine the best fit it is 
generally useful to compare the AD and p values, the distribution with the 
smaller AD and larger P values best fit the data. 
These components appear to follow the lognormal distribution more 
closely. 
 
 
  
Table 6 Summary of the in-vivo reproducibility study 
  Assignment  Q (m/z) tr / s ln A RSD
1 Propanoic Acid 74  312 7.62  18.2  
2  Unassigned 106  1098 5.77  15.7  
3  2-phenoxy Ethanol  94  1218 4.94  6.4  
4  n-Hexyl Salicylate  120  1962 6.68  9.9  
5  Benzoic acid ester -1 123  2616 10.29  8.8  
6 Benzoic acid ester-2 123  2724 10.27  9.4  
 
Note.  Q, Quantitation ion  (m/z); tr ,retention time / s;  A, mean chromato-
graphic peak area / kcount s; and,  RSD, relative standard deviation (%). 
tr / s Normal Distribution Lognormal Distribution 
 AD p AD p 
1098 0.930 0.007 0.417 0.214 
1218 0.336 0.364 0.213 0.733 
1776 0.336 0.364 0.169 0.882 
1962 0.311 0.428 0.158 0.904 
2334 1.081 <0.005 0.300 0.459 
2400 0.740 0.025 0.256 0.570 
2616 0.422 0.207 0.169 0.884 
2724 0.740 0.025 0.256 0.570 
